Published in Endocr Rev on June 01, 2000
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 3.16
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J (2006) 1.77
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer (2008) 1.55
Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res (2006) 1.44
Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell Immunol (2008) 1.42
The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis (2005) 1.30
The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta (2010) 1.29
The IGF axis and hepatocarcinogenesis. Mol Pathol (2001) 1.26
Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr (2011) 1.26
Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol (2009) 1.24
Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol (2011) 1.22
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res (2005) 1.22
Obesity, insulin resistance and cancer risk. Yonsei Med J (2005) 1.20
Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet (2009) 1.20
Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet (2010) 1.16
The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5. EMBO J (2001) 1.08
Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res (2009) 1.08
Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev (2010) 1.07
Diabetes and risk of cancer. ISRN Oncol (2013) 1.06
Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci U S A (2003) 1.05
Computational drug discovery. Acta Pharmacol Sin (2012) 1.04
Insulin-like growth factor I controls adhesion strength mediated by alpha5beta1 integrins in motile carcinoma cells. Mol Biol Cell (2004) 1.04
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer (2010) 1.04
Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol (2010) 1.03
Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer (2007) 1.01
Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol (2013) 1.00
Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther (2011) 1.00
Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer (2007) 1.00
RNA-binding protein insulin-like growth factor mRNA-binding protein 3 (IMP-3) promotes cell survival via insulin-like growth factor II signaling after ionizing radiation. J Biol Chem (2011) 0.98
Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med (2014) 0.97
A systematic review and meta-analysis of the relationship between body size and testicular cancer. Br J Cancer (2010) 0.97
Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a population-based cohort study. J Gastroenterol (2012) 0.96
miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2. Oncol Lett (2013) 0.95
Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2005) 0.95
Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res (2008) 0.95
Cancer, physical activity, and exercise. Compr Physiol (2012) 0.94
Key issues in the modes of action and effects of trichloroethylene metabolites for liver and kidney tumorigenesis. Environ Health Perspect (2006) 0.94
Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. World J Gastroenterol (2014) 0.93
Polymorphism of the insulin gene is associated with increased prostate cancer risk. Br J Cancer (2003) 0.92
Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol (2010) 0.92
Targeting of the protein interaction site between FAK and IGF-1R. Biochem Biophys Res Commun (2009) 0.92
Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk: a meta-analysis. PLoS One (2012) 0.91
Molecular biology of head and neck cancer: risks and pathways. Hematol Oncol Clin North Am (2008) 0.91
Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrix metalloproteinase-7 in resected non-small cell lung cancer. Exp Ther Med (2012) 0.91
Gallstones, a cholecystectomy, chronic pancreatitis, and the risk of subsequent pancreatic cancer in diabetic patients: a population-based cohort study. J Gastroenterol (2012) 0.91
The contribution of growth hormone to mammary neoplasia. J Mammary Gland Biol Neoplasia (2008) 0.90
Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk. Carcinogenesis (2009) 0.89
Controversies in the definition and treatment of idiopathic short stature (ISS). J Clin Res Pediatr Endocrinol (2009) 0.89
15-lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells. Neoplasia (2004) 0.89
Impact of diabetes on overall and cancer-specific mortality in colorectal cancer patients. J Cancer Res Clin Oncol (2013) 0.89
Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck (2011) 0.89
βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway. PLoS One (2013) 0.87
IGF-II promoter methylation and ovarian cancer prognosis. J Cancer Res Clin Oncol (2007) 0.87
Genetic variation in insulin-like growth factors and brain tumor risk. Neuro Oncol (2008) 0.87
Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer (2004) 0.87
Growth hormone and its disorders. Postgrad Med J (2006) 0.87
Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Mol Cell Endocrinol (2010) 0.87
Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605. BMC Cancer (2009) 0.86
Lactose intolerance and risk of lung, breast and ovarian cancers: aetiological clues from a population-based study in Sweden. Br J Cancer (2014) 0.86
Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer (2012) 0.85
Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung. Exp Ther Med (2011) 0.85
Type 2 diabetes mellitus and risk of malignant melanoma: a systematic review and meta-analysis of cohort studies. Iran J Public Health (2014) 0.84
Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing. J Oncol Pract (2011) 0.84
Current perspectives between metabolic syndrome and cancer. Oncotarget (2016) 0.84
Polysaccharides from Capsosiphon fulvescens stimulate the growth of IEC-6 Cells by activating the MAPK signaling pathway. Mar Biotechnol (NY) (2010) 0.84
Effects of high-isoflavone soy diet vs. casein protein diet and obesity on DMBA-induced mammary tumor development. Oncol Lett (2010) 0.83
Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma. PLoS One (2014) 0.83
NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation. Cancer Res (2009) 0.83
An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer (2010) 0.83
Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy. Korean J Urol (2012) 0.83
Genetic polymorphisms in IGF-I and IGFBP-3 are associated with prostate cancer in the Chinese population. PLoS One (2014) 0.82
Racial variation in vitamin D cord blood concentration in white and black male neonates. Cancer Causes Control (2012) 0.82
A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines. BMC Complement Altern Med (2011) 0.82
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway. PLoS One (2013) 0.82
The Association between Polymorphismsin Insulin and Obesity Related Genesand Risk of Colorectal Cancer. Iran J Cancer Prev (2013) 0.82
IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival. Cell Death Dis (2014) 0.82
Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy. Cancer Metastasis Rev (2014) 0.82
Growth hormone treatment and risk of malignancy. Korean J Pediatr (2015) 0.82
Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival. Br J Cancer (2005) 0.81
The Role of Cathelicidin LL-37 in Cancer Development. Arch Immunol Ther Exp (Warsz) (2015) 0.81
IGF-IR determines the fates of BCR/ABL leukemia. J Hematol Oncol (2015) 0.81
The insulin and igf-I pathway in endocrine glands carcinogenesis. J Oncol (2012) 0.80
Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A (2005) 0.80
Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis. Int J Clin Exp Pathol (2014) 0.80
Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer Chemother Pharmacol (2013) 0.80
Role of insulin-like growth factor binding protein-4 in prevention of colon cancer. World J Surg Oncol (2007) 0.80
Expression of insulin-like growth factor-1 receptor in keloid and hypertrophic scar. Clin Exp Dermatol (2014) 0.79
siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells. J Cancer Res Clin Oncol (2007) 0.79
Pediatric brain tumor treatment: growth consequences and their management. Pediatr Endocrinol Rev (2010) 0.79
The association between change in body mass index and upper aerodigestive tract cancers in the ARCAGE project: multicenter case-control study. Int J Cancer (2011) 0.79
The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis. J Mol Histol (2011) 0.78
Ox-LDL upregulates CRP expression through the IGF2 pathway in THP-1 macrophages. Inflammation (2015) 0.78
Induction of apoptosis by a peptide from Porphyra yezoensis: regulation of the insulin-like growth factor I receptor signaling pathway in MCF-7 cells. Int J Oncol (2014) 0.78
Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis. Eur J Nutr (2012) 0.78
The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus. Adv Pharm Bull (2014) 0.78
Genetic and dietary determinants of insulin-like growth factor (IGF)-1 and IGF binding protein (BP)-3 levels among Chinese women. PLoS One (2014) 0.78
The stimulation of IGF-1R expression by Lewis(y) antigen provides a powerful development mechanism of epithelial ovarian carcinoma. Int J Mol Sci (2011) 0.78
IGF-IR in patients with advanced colorectal cancer in correlation with certain clinico-morphological factors: Initial report. Oncol Lett (2011) 0.78
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg (2001) 11.58
Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med (2011) 2.30
Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 2.19
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia (2009) 1.81
The surgical treatment of metastatic spinal tumors within the intradural extramedullary compartment. J Neurosurg (1996) 1.71
Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth. J Neurosurg (2000) 1.70
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol (2011) 1.70
The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) (2010) 1.61
Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia (2005) 1.58
Transthoracic vertebrectomy for metastatic spinal tumors. J Neurosurg (1998) 1.55
Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. Endocr Pract (2001) 1.44
Postoperative swelling of pericranial pedicle graft producing intracranial mass effect. Report of two cases. J Neurosurg (1999) 1.41
Effects of heparin on renal morphology and albuminuria in experimental diabetes. Am J Physiol (1996) 1.40
Insulin-like growth factor I - a novel biomarker of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg (2011) 1.40
Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. Cancer Res (2000) 1.37
Colorectal carcinoma and brain metastasis: distribution, treatment, and survival. Ann Surg Oncol (1996) 1.36
Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia (2004) 1.28
Changes in muscle size and MHC composition in response to resistance exercise with heavy and light loading intensity. J Appl Physiol (1985) (2008) 1.22
Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. J Clin Endocrinol Metab (2009) 1.17
Single-stage posterior vertebrectomy and replacement combined with posterior instrumentation for spinal metastasis. J Neurosurg (1996) 1.15
The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology (2000) 1.11
Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut (1999) 1.11
Simultaneous anterior-posterior approach to the thoracic and lumbar spine for the radical resection of tumors followed by reconstruction and stabilization. J Neurosurg (2001) 1.09
Elective laparoscopic cholecystectomy nearly abolishes the postoperative hepatic catabolic stress response. Ann Surg (1995) 1.09
Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia (2010) 1.08
Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis (1996) 1.08
A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann Thorac Surg (1999) 1.07
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med (2011) 1.07
Use of pedicle screw fixation in the management of malignant spinal disease: experience in 100 consecutive procedures. J Neurosurg (2001) 1.07
Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia (2004) 1.05
Comparative effects of IGF-I and insulin on the glucose transporter system in rat muscle. Am J Physiol (1994) 1.04
Images in clinical medicine. Pituitary gigantism. N Engl J Med (1999) 1.04
GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH. J Clin Endocrinol Metab (2001) 1.03
Vertex epidural hematoma: surgical versus conservative management: two case reports and review of the literature. Neurosurgery (1999) 1.02
Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia (2008) 1.02
Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice. Diabetologia (2007) 1.00
High prevalence of normal tests assessing hypercortisolism in subjects with mild and episodic Cushing's syndrome suggests that the paradigm for diagnosis and exclusion of Cushing's syndrome requires multiple testing. Horm Metab Res (2010) 0.99
Relationship of adiposity with arterial stiffness as mediated by adiponectin in older men and women: the Hoorn Study. Eur J Endocrinol (2008) 0.99
Effect of administration of oral contraceptives in vivo on collagen synthesis in tendon and muscle connective tissue in young women. J Appl Physiol (1985) (2008) 0.99
Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty. Clin Endocrinol (Oxf) (1996) 0.99
Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg (2001) 0.98
Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J Clin Endocrinol Metab (1999) 0.97
Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab (2003) 0.97
Surgical resection of calvarial metastases overlying dural sinuses. Neurosurgery (2001) 0.96
Left ventricular dysfunction in hypertensive patients with Type 2 diabetes mellitus. Diabet Med (2005) 0.96
Compensatory increase in AQP2, p-AQP2, and AQP3 expression in rats with diabetes mellitus. Am J Physiol Renal Physiol (2001) 0.95
Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab (2003) 0.95
Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg (1999) 0.93
Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. J Intern Med (2006) 0.93
Renal enlargement precedes renal hyperfiltration in early experimental diabetes in rats. J Am Soc Nephrol (2000) 0.93
Zinc ions in beta-cells of obese, insulin-resistant, and type 2 diabetic rats traced by autometallography. APMIS (2003) 0.92
Association of fasting glucagon and proinsulin concentrations with insulin resistance. Diabetologia (2007) 0.92
Time-dependent intestinal adaptation and GLP-2 alterations after small bowel resection in rats. Am J Physiol Gastrointest Liver Physiol (2001) 0.92
Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia (2006) 0.92
The insulin-like growth factor system and markers of inflammation in adult patients with inflammatory bowel disease. Horm Res (2005) 0.91
Changes in calcitropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study. Osteoporos Int (2012) 0.91
Increased levels of alpha-defensin (-1, -2 and -3) in type 1 diabetic patients with nephropathy. Nephrol Dial Transplant (2007) 0.90
Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol (2001) 0.90
Combined chest wall resection with vertebrectomy and spinal reconstruction for the treatment of Pancoast tumors. J Neurosurg (1999) 0.89
Concentrations, release, and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-I, and growth hormone in different vascular beds in patients with cirrhosis. J Clin Endocrinol Metab (1995) 0.89
Transforming growth factor-beta1 stimulates the production of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in human bone marrow stromal osteoblast progenitors. J Endocrinol (2001) 0.89
Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney. Endocrinology (1997) 0.89
Management of benign and aggressive intracranial meningiomas. Oncology (Williston Park) (1996) 0.89
Impaired vascular function during short-term poor glycaemic control in Type 1 diabetic patients. Diabet Med (2005) 0.88
Anterior approaches to the thoracic spine in patients with cancer: indications and results. Ann Thorac Surg (1997) 0.88
Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int (1999) 0.87
Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol (1999) 0.87
Role of insulin-like growth factor-1 and growth hormone in growth inhibition induced by magnesium and zinc deficiencies. Br J Nutr (1991) 0.87
Short-term effects of growth hormone on fuel oxidation and regional substrate metabolism in normal man. J Clin Endocrinol Metab (1990) 0.87
Expression of neurotrophic factors in diabetic muscle--relation to neuropathy and muscle strength. Brain (2009) 0.87
Growth hormone and insulin-like growth factor-I: effects on the growth of glioma cell lines. Growth Horm IGF Res (2001) 0.87
Local administration of insulin-like growth factor-I (IGF-I) stimulates tendon collagen synthesis in humans. Scand J Med Sci Sports (2012) 0.86
Homologous growth hormone accelerates bone healing--a biomechanical and histological study. Bone (2003) 0.86
Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod (2007) 0.85
The relationship between the circulating IGF system and the presence of retinopathy in Type 1 diabetic patients. Diabet Med (2003) 0.85
Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice. J Endocrinol (2002) 0.85
Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Horm Metab Res (2005) 0.85
Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol (1997) 0.85
Inhibition of renal ornithine decarboxylase activity prevents kidney hypertrophy in experimental diabetes. Am J Physiol (1993) 0.85
Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res (2005) 0.85
The development of microalbuminuria is associated with raised longitudinal adiponectin levels in female but not male adolescent patients with type 1 diabetes. Diabetologia (2008) 0.84
Macrosomia associated with maternal serum insulin-like growth factor-I and -II in diabetic pregnancy. Obstet Gynecol (2001) 0.84
Estrogen reduces pro-inflammatory cytokines in rodent adipose tissue: studies in vivo and in vitro. Horm Metab Res (2003) 0.84
Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study. J Bone Miner Res (1995) 0.84
Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg (1999) 0.84
Hemangioblastomas and other uncommon intramedullary tumors. J Neurooncol (2000) 0.84
No evidence of insulin-like growth factor-binding protein 3 proteolysis during a maximal exercise test in elite athletes. J Clin Endocrinol Metab (2001) 0.84
The pharmacokinetics of octreotide in cirrhosis and in healthy man. J Hepatol (1997) 0.83
Effect of GH/IGF-I deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats. Am J Physiol (1997) 0.83
Diurnal variation of cerebrospinal fluid immunoreactive corticotropin-releasing hormone levels in healthy volunteers. J Clin Endocrinol Metab (1994) 0.83
Complement activation and cardiovascular disease. Horm Metab Res (2008) 0.83
Identification of differentially expressed genes in the kidneys of growth hormone transgenic mice. Growth Horm IGF Res (2010) 0.83